General Information of Drug (ID: DMAL2OW)

Drug Name
PRX-005 Drug Info
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMAL2OW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LMT-X DMOFIBM Acute myeloid leukaemia 2A60 Phase 3 [2]
Davunetide DMD7K9X Cognitive impairment 6D71 Phase 3 [3]
TRx0237 DM0QNF4 Alzheimer disease 8A20 Phase 3 [4]
E2814 DMZ3Q59 Alzheimer disease 8A20 Phase 2/3 [5]
PBT-2 DMKWGS1 Alzheimer disease 8A20 Phase 2 [6]
RG6100 DMEFD0B Alzheimer disease 8A20 Phase 2 [7]
Tau-binding PET tracer DM9QFW2 Alzheimer disease 8A20 Phase 2 [3]
BIIB092 DM263RP Progressive supranuclear palsy 8A00.10 Phase 2 [7]
Semorinemab DMA17VD Alzheimer disease 8A20 Phase 2 [8]
Bepranemab DMRQIJO Alzheimer disease 8A20 Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Microtubule-associated protein tau (MAPT) TTS87KH TAU_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of Prothena
2 Clinical pipeline report, company report or official report of TauRx.
3 Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
4 Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr Alzheimer Res. 2020;17(3):285-296.
5 Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease. Acta Neuropathol Commun. 2020 Feb 4;8(1):13.
6 PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. Sci Transl Med. 2021 May 12;13(593):eabb2639.
9 Immunotherapy for Alzheimer's disease: targeting beta-amyloid and beyond. Transl Neurodegener. 2022 Mar 18;11(1):18.